Not Yet RecruitingPhase 1

A Study to Evaluate the Safety and Pharmacokinetics of RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

160 participantsStarted 2026-05-01

Plain-language summary

This study will evaluate safety, pharmacokinetics (PK), clinical activity and pharmacodynamics (PD) of RO7851624 in participants with RRMM who are triple-class exposed (treated with proteasome inhibitors \[PIs\], immunomodulators \[IMiDs\], and anti-cluster of differentiation 38 \[anti-CD38\] monoclonal antibodies), and have limited remaining standard treatment options due to refractoriness, intolerance, or multiple prior therapies.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Life expectancy of at least 12 weeks. * Diagnosis of multiple myeloma per International Myeloma Working Group (IMWG) criteria. * Measurable disease. Exclusion Criteria: * Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) with insufficient washout prior to ﬁrst dose of study treatment. * Autologous stem cell transplant (SCT) with insufficient time prior to ﬁrst dose of study treatment. * Prior allogeneic SCT. * Prior solid organ transplantation.

What they're measuring

Percentage of Participants With Adverse Events (AEs)

Timeframe: Up to approximately 2 years

Trial details

NCT IDNCT07558915

SponsorGenentech, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2030-07-01

Contact for this trial

Reference Study ID Number: GO46140 https://forpatients.roche.com/

888-662-6728 (U.S. and Canada) global-roche-genentech-trials@gene.com

View on ClinicalTrials.gov More Relapsed/Refractory Multiple Myeloma trials